Linezolid Induced Adverse Drug Reactions - An Update

被引:71
作者
Kishor, Kamal [1 ]
Dhasmana, Neha [2 ,4 ]
Kamble, Shashank Shivaji [2 ,4 ]
Sahu, Roshan Kumar [3 ,4 ]
机构
[1] Inst Pesticide Formulat Technol, Gurgaon 122016, Haryana, India
[2] Inst Genom & Integrat Biol, New Delhi 110007, India
[3] CSIR, Open Source Drug Discovery Unit, New Delhi 110001, India
[4] Acad Sci & Innovat Res AcSIR, New Delhi, India
关键词
Adverse drug reactions; anti-tuberculosis drugs; drug interactions; linezolid; optic neuropathy; thrombocytopenia; INDUCED LACTIC-ACIDOSIS; RISK-FACTORS; PROTEIN-SYNTHESIS; OPTIC NEUROPATHY; MDR-TB; THROMBOCYTOPENIA; TOLERABILITY; INHIBITION; EFFICACY; PATIENT;
D O I
10.2174/1389200216666151001121004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Treatment regimen recommended for resistant tuberculosis consists of various drugs and these drugs are prescribed for at least 12-15 months. Such a long duration therapy and high dose of antibiotics result in adverse drug reactions (ADRs). ADRs may lead to various complications in disease management like replacement of drugs, dose increment, therapy withdrawal, etc. Linezolid is one of those drugs, practiced as an anti-mycobacterial agent and it is an important member of drug regimen for MDR and XDR tuberculosis. Linezolid is a broad spectrum antibiotic known for its unique mechanism of inhibition of resistant pathogenic strains. However, it causes serious adverse effects like thrombocytopenia, optic neuropathy, peripheral neuropathy, lactic acidosis, etc. Literature suggests that Linezolid can cause severe ADRs which affect patient compliance and hinder in therapy to a larger extent. Recent studies confirm the possibility of ADRs to be predicted with genetic make-up of individuals. To effectively deliver the available treatment regimen and ensure patient compliance, it is important to manage ADRs more efficiently. The role of pharmacogenomics in reducing adverse drug effects has been recently explored. In the present review, we discussed about Linezolid induced adverse drug reactions, mechanisms and genetic associations.
引用
收藏
页码:553 / 559
页数:7
相关论文
共 50 条
  • [1] Thrombocytopenia associated with linezolid therapy
    Attassi, K
    Hershberger, E
    Alam, R
    Zervos, MJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 695 - 698
  • [2] Adverse Effects of Antimicrobials via Predictable or Idiosyncratic Inhibition of Host Mitochondrial Components
    Barnhill, Alison E.
    Brewer, Matt T.
    Carlson, Steve A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (08) : 4046 - 4051
  • [3] Mechanisms for linezolid-induced anemia and thrombocytopenia
    Bernstein, WB
    Trotta, RF
    Rector, JT
    Tjaden, JA
    Barile, AJ
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (04) : 517 - 520
  • [4] Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism
    Carson, John
    Cerda, Jorge
    Chae, Jong-Hee
    Hirano, Michio
    Maggiore, Peter
    [J]. PHARMACOTHERAPY, 2007, 27 (05): : 771 - 774
  • [5] Chuchottaworn Charoen, 2012, J Med Assoc Thai, V95 Suppl 8, pS1
  • [6] Rapid-onset, linezolid-induced lactic acidosis in MELAS
    Cope, Thomas E.
    McFarland, Robert
    Schaefer, Andrew
    [J]. MITOCHONDRION, 2011, 11 (06) : 992 - 993
  • [7] Linezolid-induced inhibition of mitochondrial protein synthesis
    De Vriese, AS
    Van Coster, R
    Smet, J
    Seneca, S
    Lovering, A
    Van Haute, LL
    Vanopdenbosch, LJ
    Martin, JJ
    Ceuterick-de Groote, C
    Vandecasteele, S
    Boelaert, JR
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) : 1111 - 1117
  • [8] Linezolid-Induced Lactic Acidosis in Two Liver Transplant Patients with the Mitochondrial DNA A2706G Polymorphism
    Del Pozo, J. L.
    Fernandez-Ros, N.
    Saez, E.
    Herrero, J. I.
    Yuste, J. R.
    Banales, J. M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (07) : 4227 - 4229
  • [9] Esposito L, 2007, CLIN NEPHROL, V68, P327
  • [10] Safety and tolerability of linezolid
    French, G
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 : 45 - 53